Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies.

2017-06

Christidis, Daniel

McGrath, Shannon

Perera, Marlon

Manning, Todd G

Bolton, Damien M

Lawrentschuk, Nathan

Aquablation

Benign prostatic hypertrophyprostatic artery embolization

Minimally invasive surgical therapies

Prostatic stenting

Journal Article

0000-0003-2951-3726

0000-0002-1138-6389

0000-0001-5609-3769

0000-0002-5145-6783

0000-0001-8553-5618

10.1016/j.prnil.2017.01.007

The prevalence of benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms increases with our ageing population. Treatment of BPH traditionally begins with medical therapy and surgical intervention is then considered for those whose symptoms progress despite treatment. Minimally invasive surgical therapies have been developed as an intermediary in the treatment of BPH with the aim of decreasing the invasiveness of interventions. These therapies also aim to reduce morbidity and dysfunction related to invasive surgical procedures. Multiple treatment options exist in this group including mechanical and thermo-ablative strategies. Emerging therapies utilizing differing technologies range from the established to the experimental. We review the current literature related to these minimally invasive therapies and the evidence of their effectiveness in treating BPH. The role of minimally invasive surgical therapies in the treatment of BPH is still yet to be strongly defined. Given the experimental nature of many of the modalities, further study is required prior to their recommendation as alternatives to invasive surgical therapy. More mature evidence is required for the analysis of durability of effect of these therapies to make robust conclusions of their effectiveness.

link

Prostate international 2017; 5(2): 41-46

Prostate international

2287-8882